avapro and bradykinin
avapro has been researched along with bradykinin in 5 studies
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fox, M; Panchal, BC; Trippodo, NC | 1 |
| Brecher, P; Chobanian, AV; Hope, S | 1 |
| Ader, JL; Bascands, JL; Girolami, JP; Marin-Castaño, ME; Neau, E; Pecher, C; Praddaude, F; Schanstra, JP | 1 |
| Dendorfer, A; Hauke, D; Krause, W; Schultheiss, HP; Siems, WE; Spillmann, F; Tschöpe, C; Walther, T | 1 |
| Addabbo, F; Carratù, MR; Iacobazzi, D; Leo, V; Montagnani, M; Potenza, MA; Sgarra, L | 1 |
Other Studies
5 other study(ies) available for avapro and bradykinin
| Article | Year |
|---|---|
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Topics: Alanine; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Blood Volume; Bradykinin; Cricetinae; Drug Synergism; Enalaprilat; Heart Failure; Irbesartan; Male; Neprilysin; Tetrazoles; Vasodilation; Ventricular Function, Left | 1995 |
Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Aortic Diseases; Arteriosclerosis; Biphenyl Compounds; Blood Pressure; Bradykinin; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Follow-Up Studies; Irbesartan; Peptidyl-Dipeptidase A; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Dinoprostone; Drug Administration Schedule; Enzyme Activation; Hypotension; Irbesartan; Kidney; Male; Mice; Mice, Knockout; Nephrons; Organ Specificity; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Bradykinin B1; Receptor, Bradykinin B2; Receptors, Bradykinin; RNA, Messenger; Tetrazoles; Time | 2002 |
AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Bradykinin; Hemodynamics; Irbesartan; Isoquinolines; Male; Myocardial Infarction; Myocardium; Neprilysin; Quinapril; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrahydroisoquinolines; Tetrazoles | 2002 |
Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Heart; Hemodynamics; In Vitro Techniques; Irbesartan; Ischemic Postconditioning; Losartan; Male; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Systole; Tetrazoles | 2014 |